Patents by Inventor Danqing Feng
Danqing Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406885Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, A1, A2, R1-R7, R8a, R8b, R9a, R9b, R10 and R11 are as herein described. can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: June 13, 2023Publication date: December 21, 2023Applicant: MERCK SHARP & DOHME LLCInventors: Faben A. Cruz, Danqing Feng, Zhuyan Guo, Jennifer Hanisak, Jennifer L. Hickey, Charles Lee Jayne, Ahmet Kekec, Michael Man-Chu Lo, Christopher W. Plummer, Elisabetta Bianchi, Stefania Colarusso, Emanuela Nizi, Francesca Pavone, Ali Munaim Yousif
-
Publication number: 20230310551Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: August 24, 2021Publication date: October 5, 2023Applicant: Merck Sharp & Dohme LLCInventors: Christina B. Madsen-Duggan, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
-
Publication number: 20220273770Abstract: Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.Type: ApplicationFiled: July 23, 2020Publication date: September 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Andrew J. Kassick, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Publication number: 20220233647Abstract: Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.Type: ApplicationFiled: June 1, 2020Publication date: July 28, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Songnian Lin, Dmitri A. Pissarnitski, Brenda Pipik, Lin Yan, Yuping Zhu
-
Patent number: 11041009Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: GrantFiled: March 19, 2018Date of Patent: June 22, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Patent number: 10800827Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 26, 2018Date of Patent: October 13, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10689430Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: May 23, 2017Date of Patent: June 23, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20200087375Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: ApplicationFiled: March 19, 2018Publication date: March 19, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, David N. Hunter, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Zhiqiang Zhao, Yuping Zhu
-
Publication number: 20190177393Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: May 23, 2017Publication date: June 13, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20190092833Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10183981Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: June 13, 2018Date of Patent: January 22, 2019Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Publication number: 20180291078Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10017556Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 19, 2015Date of Patent: July 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Publication number: 20180110863Abstract: Insulin conjugates comprising an insulin analog molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: ApplicationFiled: April 4, 2016Publication date: April 26, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Niels C. Kaarsholm, Songnian Lin, Ravi P. Nargund, Lin Yan
-
Patent number: 9868733Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 19, 2013Date of Patent: January 16, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan
-
Publication number: 20170355743Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: November 19, 2015Publication date: December 14, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 9840627Abstract: The present invention provides application of camptothecin and derivatives thereof as antifouling agent, relating to camptothecin. Application of camptothecin and derivatives thereof as antifouling agent for facilities in water is provided, wherein the antifouling agent contains camptothecin and/or at least one of its derivatives. The application of camptothecin and derivatives thereof as antifouling agent for facilities in water can be used to prevent attachment of marine or freshwater micro-fouling organisms and/or large fouling organisms to the surfaces of facilities in the sea, lake, river or pool. The antifouling agent may also be used in mixture with other antifouling substance. Antifouling method for artificial facilities in water is provided. An antifouling paint for facilities in water is provided. Camptothecin and its derivatives have significant inhibitory activity to the attachment of fouling organisms, i.e.Type: GrantFiled: October 16, 2013Date of Patent: December 12, 2017Assignee: Xiamen UniversityInventors: Danqing Feng, Caihuan Ke, Wei Wang, Xiang Wang, Jian He, Hui Liu
-
Publication number: 20170107268Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: November 19, 2015Publication date: April 20, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 9556193Abstract: The novel benzimidazole hexahydrofuro[3,2-B]furan derivatives of the present invention are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 16, 2013Date of Patent: January 31, 2017Assignee: Merck Shapr & Dohme Corp.Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Patent number: 9540364Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 15, 2013Date of Patent: January 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu